Unlock AI-driven, actionable R&D insights for your next breakthrough.

Croscarmellose Sodium In Oral Solid Dosage Forms: Particle Size Optimization And Formulation Strategies For Enhanced Disintegration

NOV 17, 202654 MINS READ

Want An AI Powered Material Expert?
Here's Patsnap Eureka Materials!
Croscarmellose Sodium serves as a critical superdisintegrant in oral solid dosage forms, enabling rapid tablet disintegration and drug release through its unique swelling mechanism. Recent innovations demonstrate that particle size engineering—specifically utilizing median particle sizes ≥56 μm at concentrations ≥4% w/w—can dramatically reduce disintegration times to under 20 seconds 12. This article examines the structure-property relationships, formulation parameters, and application-specific strategies that pharmaceutical scientists must consider when optimizing Croscarmellose Sodium for immediate-release and specialized delivery systems.
Want to know more material grades? Try Patsnap Eureka Material.

Molecular Structure And Functional Mechanism Of Croscarmellose Sodium In Disintegration

Croscarmellose Sodium is a cross-linked polymer derived from carboxymethylcellulose sodium, engineered to provide superior disintegration performance in compacted oral dosage forms 39. The cross-linking introduces three-dimensional network structures that resist dissolution while enabling rapid water uptake and volumetric expansion. Upon contact with aqueous media, the polymer chains undergo rapid hydration, generating localized swelling pressures (typically 10–50 kPa depending on cross-link density) that mechanically disrupt the tablet matrix 12.

The disintegration mechanism operates through three concurrent pathways:

  • Wicking action: Capillary forces draw water into tablet pores, facilitated by the hydrophilic carboxymethyl groups (–CH₂COONa) distributed along the cellulose backbone 39.
  • Swelling pressure: Hydrated polymer chains exert radial forces as the gel layer expands, creating internal stresses exceeding typical tablet tensile strengths (1–3 MPa) 18.
  • Strain recovery: The cross-linked network exhibits elastic rebound upon compression release, generating microchannels that accelerate water penetration 213.

The degree of substitution (DS) for carboxymethyl groups typically ranges from 0.6 to 0.95 per anhydroglucose unit, with higher DS values correlating with faster hydration kinetics but reduced mechanical stability during compression 3. The cross-linking density, controlled during synthesis via esterification or ether bond formation, must be optimized to balance swelling capacity (typically 400–800% volume increase) against premature gel formation that could retard drug release 9.

Particle Size Engineering For Optimized Disintegration Performance In Croscarmellose Sodium Formulations

Conventional pharmaceutical excipient guidelines recommend Croscarmellose Sodium at 0.5–5% w/w with median particle sizes of 30–50 μm 39. However, systematic investigations reveal that coarser particles (≥56 μm) at elevated concentrations (≥4% w/w) deliver superior disintegration kinetics across diverse active pharmaceutical ingredients (APIs) and manufacturing processes 128.

Particle Size Specifications And Performance Correlations

Patent literature establishes critical particle size thresholds for enhanced performance 1213:

  • Median particle size (d₅₀): ≥56 μm, with optimal ranges of 70–100 μm for immediate-release tablets; extended ranges of 150–342 μm demonstrate efficacy in specialized applications without exceeding 500 μm to maintain compressibility 12.
  • Volume mean diameter: For fine-particle variants, d₄₃ ≤40 μm with d₅₀ = 5–36 μm enables uniform distribution in low-dose formulations (0.1–1% w/w) and orally disintegrating tablets (ODTs) 101112.
  • Specific surface area: Fine-particle grades exhibit ≥0.3 m²/g, enhancing wicking efficiency in moisture-sensitive APIs, whereas coarser grades (0.1–0.2 m²/g) reduce hygroscopicity during storage 1011.

Disintegration time correlates inversely with particle size above 56 μm: tablets containing 6% w/w Croscarmellose Sodium at d₅₀ = 86 μm disintegrate in 12–18 seconds (USP <701> apparatus, 37°C deionized water), compared to 25–35 seconds for 50 μm material at equivalent concentration 18. This phenomenon arises from increased interparticle void volume in coarser grades, facilitating faster water ingress before significant gel layer formation 2.

Concentration Optimization Strategies

Elevated Croscarmellose Sodium levels (≥4% w/w) are essential for APIs with poor wettability or high-dose formulations (>200 mg API per tablet) 128:

  • Standard immediate-release tablets: 4–8% w/w provides disintegration times <30 seconds for tablets weighing 200–500 mg 113.
  • High-dose formulations: 10–15% w/w compensates for reduced porosity in tablets containing ≥50% w/w API, maintaining disintegration <60 seconds 28.
  • Catechol derivative formulations: Entacapone and nitecapone require 10–14% w/w Croscarmellose Sodium to achieve >80% dissolution within 15 minutes, attributed to their crystalline hydrophobic nature (log P = 2.5–3.2) 39.

Upper concentration limits (typically ≤20% w/w for immediate release, ≤30% w/w for suspension tablets) prevent excessive friability (<0.8% mass loss, USP <1216>) and maintain tablet hardness (50–100 N) 124.

Formulation Design Principles For Croscarmellose Sodium In Oral Solid Dosage Forms

Excipient Compatibility And Synergistic Combinations

Croscarmellose Sodium functions optimally when paired with complementary excipients that balance mechanical strength, flow properties, and disintegration kinetics 5614:

  • Water-soluble fillers: Mannitol (55–70% w/w, particle size 30–300 μm) provides rapid dissolution matrix for ODTs while maintaining compactability; lactose and dextrose offer cost-effective alternatives for conventional tablets 617.
  • Binders: Hydroxypropyl cellulose (HPC) or hydroxypropyl methylcellulose (HPMC) at 2–5% w/w ensures adequate tablet integrity (tensile strength 1.5–2.5 MPa) without impeding disintegration when Croscarmellose Sodium exceeds 6% w/w 514.
  • Microcrystalline cellulose (MCC): Co-processing with 10–20% w/w MCC (e.g., CEOLUS PH-101) enhances compressibility and provides elastic recovery, critical for direct compression of low-dose APIs (<10 mg) 51416.
  • Lubricants: Magnesium stearate (0.5–1.5% w/w) must be added as the final blending step (mixing time <3 minutes) to prevent hydrophobic coating of Croscarmellose Sodium particles, which can increase disintegration time by 40–60% 617.

Intragranular Versus Extragranular Addition Strategies

The distribution of Croscarmellose Sodium within the formulation architecture significantly impacts disintegration pathways 3914:

  • Intragranular addition (incorporated during wet granulation): 2–4% w/w within granules promotes granule disintegration into primary particles, beneficial for poorly soluble APIs requiring large surface area exposure 3.
  • Extragranular addition (blended post-granulation): 4–8% w/w outside granules accelerates tablet-level disintegration through rapid water penetration along intergranular boundaries; this approach is preferred for moisture-sensitive APIs and ODT formulations 91416.
  • Dual addition (split intragranular/extragranular): Total 8–12% w/w divided 1:2 ratio (intragranular:extragranular) provides sequential disintegration—tablet breaks into granules within 10 seconds, followed by granule dispersion within 20 seconds—optimizing bioavailability for BCS Class II drugs 39.

Manufacturing Process Considerations

Croscarmellose Sodium demonstrates versatility across tabletting technologies, though process-specific adjustments are necessary 1813:

  • Direct compression: Coarse-grade Croscarmellose Sodium (d₅₀ = 70–100 μm) at 6–10% w/w blends uniformly with free-flowing excipients (Carr's index <15); compression forces of 8–15 kN yield tablets with 5–12% porosity, ideal for rapid water ingress 113.
  • Wet granulation: Fine-grade material (d₅₀ = 20–40 μm) at 3–6% w/w intragranular prevents excessive granule hardening; granulation endpoint should target 10–15% moisture content to preserve disintegrant functionality 39.
  • Dry granulation (roller compaction): Coarse-grade Croscarmellose Sodium (d₅₀ = 80–120 μm) at 8–12% w/w compensates for densification-induced porosity loss; ribbon density should not exceed 1.1 g/cm³ to maintain disintegration <45 seconds 8.

Applications Of Croscarmellose Sodium Across Therapeutic Categories And Dosage Form Variants

Immediate-Release Tablets For Rapid Systemic Absorption

Croscarmellose Sodium serves as the disintegrant of choice for APIs requiring fast onset of action (Tmax <30 minutes) 1813:

  • Analgesics and antipyretics: Formulations containing ibuprofen (200–400 mg), acetaminophen (500–1000 mg), or aspirin (325–650 mg) utilize 5–8% w/w Croscarmellose Sodium (d₅₀ = 70–90 μm) to achieve disintegration <20 seconds and >85% dissolution within 30 minutes (USP Apparatus II, 75 rpm, pH 6.8 phosphate buffer) 113.
  • Cardiovascular agents: Amlodipine besylate tablets (2.5–10 mg) incorporate 3–6% w/w Croscarmellose Sodium with mannitol-based matrix to ensure uniform content (RSD <3%) and disintegration <25 seconds, critical for consistent blood pressure control 6.
  • Central nervous system drugs: Alprazolam, donepezil, and selegiline formulations employ 6–10% w/w Croscarmellose Sodium to overcome API hydrophobicity (log P = 2.0–3.5), achieving >80% release within 20 minutes 813.

Orally Disintegrating Tablets (ODTs) For Pediatric And Geriatric Populations

ODT formulations demand disintegration within 30 seconds in the oral cavity (USP <701> modified method, 6–10 mL saliva simulant at 37°C) while maintaining mechanical robustness during packaging and handling 101112:

  • Fine-particle Croscarmellose Sodium (d₅₀ = 15–30 μm, specific surface area ≥0.5 m²/g) at 0.5–2% w/w provides rapid wicking without grittiness; combined with 60–70% w/w mannitol (d₅₀ = 50–100 μm) and 2–4% w/w maltodextrin, these formulations achieve disintegration in 8–15 seconds with acceptable friability (<1.0%) 101117.
  • Domperidone ODTs (10 mg) utilize 3.5–8% w/w Croscarmellose Sodium, 10–20% w/w microcrystalline cellulose, and 1–5% w/w flavor/sweetener systems to mask bitter taste while ensuring disintegration <12 seconds 17.
  • Coating strategies: Fine-particle Croscarmellose Sodium (0.1–0.5% w/w) incorporated into taste-masking coatings (Eudragit E PO, 3–5% w/w) enables rapid coat rupture upon saliva contact, releasing sweeteners before API dissolution 1012.

Modified-Release Systems Utilizing Croscarmellose Sodium For Controlled Disintegration

Contrary to conventional wisdom, Croscarmellose Sodium enables extended-release profiles when combined with pH-modulating agents and hydrophobic matrices 47:

  • Sustained-release formulation architecture: Drug/Croscarmellose Sodium (5–15% w/w)/sodium carbonate or potassium carbonate (5–20% w/w)/magnesium oxide (5–15% w/w)/HPMC (10–20% w/w) generates alkaline microenvironment (pH 8–10) that moderates Croscarmellose Sodium swelling, extending release over 8–12 hours 47.
  • Hydrophobic base systems: Ethyl cellulose (10–20% w/w) or hydrogenated vegetable oil (5–15% w/w) retards water penetration, while Croscarmellose Sodium (8–12% w/w) provides pulsatile release as localized pH gradients develop during GI transit 47.
  • Mechanism: Sodium/potassium salts neutralize gastric acid, slowing Croscarmellose Sodium hydration in the stomach (T₅₀ = 2–3 hours); upon entry into intestinal pH (6.5–7.5), accelerated swelling releases remaining drug (T₈₀ = 6–8 hours post-dose) 47.

Veterinary Oral Solid Dosage Forms

Palatability and ease of administration drive Croscarmellose Sodium selection in companion animal formulations 6:

  • Canine and feline tablets: Amlodipine besylate (1.25–5 mg) formulated with 4–6% w/w Croscarmellose Sodium, 0.6–1.3% w/w colloidal anhydrous silica (glidant), and meat-flavored excipients disintegrate within 30 seconds when mixed with food, ensuring dose accuracy 6.
  • Chewable tablets: Coarse-grade Croscarmellose Sodium (d₅₀ = 100–150 μm) at 3–5% w/w provides texture contrast in xylitol- or sorbitol-based matrices (50–60% w/w), enhancing voluntary consumption while maintaining API stability (≥95% potency over 24 months at 25°C/60% RH) 6.

Regulatory And Quality Control Considerations For Croscarmellose Sodium In Pharmaceutical Manufacturing

Compendial Standards And Analytical Specifications

Croscarmellose Sodium must comply with pharmacopeial monographs (USP-NF, Ph. Eur., JP) that define critical quality attributes 3910:

  • Degree of substitution: 0.60–0.95 carboxymethyl groups per anhydroglucose unit, determined by titration (ASTM D1439 modified method) 3.
  • Particle size distribution: Laser diffraction (ISO 13320) with d₁₀, d₅₀, and d₉₀ reported; span [(d₉₀ – d₁₀)/d₅₀] should be 1.5–3.0 for uniform performance 11011.
  • Moisture content: 5–8% w/w (Karl Fischer titration, USP <921>) to maintain functionality without promoting microbial growth 39.
  • pH (1% aqueous slurry): 5.0–7.5, ensuring compatibility with acid-labile APIs 39.
  • Heavy metals: ≤20 ppm (USP <231>), residual solvents per ICH Q3C guidelines 3.

Process Validation And In-Process Controls

Critical process parameters (CPPs) for Croscarmellose Sodium-containing formulations require validation per ICH

OrgApplication ScenariosProduct/ProjectTechnical Outcomes
FMC CORPORATIONImmediate-release tablets for analgesics, cardiovascular agents, and CNS drugs requiring rapid onset (Tmax <30 minutes); suspension tablets for pediatric/geriatric populations; direct compression and wet granulation manufacturing processes.Croscarmellose Sodium (Coarse Grade)Median particle size ≥56 μm at ≥4% w/w concentration achieves tablet disintegration in <20 seconds, with optimized performance at 70-100 μm delivering 12-18 second disintegration times compared to 25-35 seconds for conventional 50 μm grades.
FMC CORPORATIONOrally disintegrating tablets (ODTs) for pediatric and geriatric patients requiring disintegration within 30 seconds in oral cavity; taste-masking coating systems; low-dose API formulations requiring uniform content distribution.Fine Particle Croscarmellose SodiumMedian particle size 5-36 μm with specific surface area ≥0.3 m²/g at 0.5-2% w/w enables rapid wicking and disintegration in 8-15 seconds for orally disintegrating tablets while maintaining mechanical robustness (friability <1.0%).
ORION CORPORATIONParkinson's disease treatment formulations requiring enhanced release rates of poorly soluble catechol-O-methyltransferase (COMT) inhibitors; high-dose tablets (>200 mg API) with challenging wettability profiles.Entacapone/Nitecapone TabletsCroscarmellose sodium at 10-14% w/w concentration overcomes hydrophobic crystalline nature of catechol derivatives (log P 2.5-3.2), achieving >80% dissolution within 15 minutes for immediate therapeutic effect.
SHIONOGI & CO. LTD.Sustained-release oral solid dosage forms requiring controlled disintegration and pH-modulated release profiles; drugs requiring protection from gastric degradation with targeted intestinal absorption.Extended Release Formulation SystemCroscarmellose sodium (5-15% w/w) combined with sodium/potassium carbonate (5-20% w/w) and magnesium oxide (5-15% w/w) creates alkaline microenvironment (pH 8-10) that moderates swelling, extending drug release over 8-12 hours with pulsatile intestinal delivery.
Sumitomo Dainippon Pharma Co. Ltd.Digestive disease treatments, psychoneurological disorder medications, and urinary disease therapies requiring rapid dissolution and consistent bioavailability; formulations containing moisture-sensitive APIs with 5-20% w/w drug loading.Solid Oral Dosage Forms with Water-Soluble ExcipientsCroscarmellose sodium (1-10% w/w) combined with mannitol matrix and water-soluble polymer binders provides excellent dissolution properties while maintaining tablet integrity (tensile strength 1.5-2.5 MPa) for prokinetic and neurological agents.
Reference
  • Solid forms
    PatentWO2012003181A2
    View detail
  • Solid forms
    PatentInactiveEP2588088A2
    View detail
  • New oral compaced composition comprising catechol derivatives.
    PatentInactiveMY124394A
    View detail
If you want to get more related content, you can try Eureka.

Discover Patsnap Eureka Materials: AI Agents Built for Materials Research & Innovation

From alloy design and polymer analysis to structure search and synthesis pathways, Patsnap Eureka Materials empowers you to explore, model, and validate material technologies faster than ever—powered by real-time data, expert-level insights, and patent-backed intelligence.

Discover Patsnap Eureka today and turn complex materials research into clear, data-driven innovation!

Group 1912057372 (1).pngFrame 1912060467.png